Chavez, MD, discusses the potential of tarlatamab and its use in the frontline setting for the treatment of patients with ...

In a retrospective study in patients with hepatocellular carcinoma, 40% of patients developed irAEs after receiving the first ...

During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events ...

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, MBA, FACP, FCCP, discussed the role of larotrectinib in a ...

In an interview with Targeted Oncology for Head and Neck Cancer Awareness Month, Noel Laudi, MD, MRCP, discussed the link ...

Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival ...

Sanjay K. Juneja, MD, Targeted Oncology’s first 2024 Oncology Icon, delves into his background and what drove him to pursue a ...

With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of ...

In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to ...

John M. Burke, MD, discusses results from a phase 2 study which evaluated brentuximab vedotin, nivolumab, doxorubicin, and ...

Anne P. O'Dea, MD, presents the case of a 49-year-old woman with HR+/HER2- metastatic breast cancer and offers initial ...

The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with ...